Embrace operational excellence
From discovery to delivery, we work to improve the efficiency and effectiveness of our operations. These activities support our profitable growth and free up resources to invest in innovation for patients. In everything we do, patient safety and product quality remain paramount.
2021 highlights
52%
Launch brands and growth-driver products
contribution to Innovative Medicines Division net sales
71 bn
Treatments supplied
through Novartis manufacturing sites
99.2%
Regulatory inspections
of our facilities deemed acceptable without major findings
12 064
Suppliers risk-assessed
through our third-party risk management framework